Anti-Human NKG2A/CD159a Reference Antibody (Monalizumab, RUO) (HB188016)

Datasheet Share product Copy info

Price(USD): $

Spec:

100ug
1mg

Number:

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HB188016
Description	Monalizumab (HB188016) is a research-grade recombinant antibody targeting CD159. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Humanized
Isotype	IgG4-kappa
Expression system	Mammalian Cells
Clonality	Monoclonal
Target	KLRC1, NKG2-A/NKG2-B type II integral membrane protein, NKG2-A/B-activating NK receptor, CD159 antigen-like family member A, CD159a, NK cell receptor A, NKG2A
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P26715
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names	IPH-2201, NN-8765, NNC-0141-0000-0100, NNC-141-01000, monolizumab, anti-NKG2A, humZ270, 1228763-95-8
Background	NKG2-A/NKG2-B type II integral membrane protein (CD159a/KLRC1) is a ~26 kDa protein. Immune inhibitory receptor involved in self-nonself discrimination. In complex with KLRD1 on cytotoxic and regulatory lymphocyte subsets, recognizes non-classical major histocompatibility (MHC) class Ib molecule HLA-E loaded with self-peptides derived from the signal sequence of classical MHC class Ia molecules. Enables cytotoxic cells to monitor the expression of MHC class I molecules in healthy cells and to tolerate self. Upon HLA-E-peptide binding, transmits intracellular signals through two immunoreceptor tyrosine-based inhibition motifs (ITIMs) by recruiting INPP5D/SHP-1 and INPPL1/SHP-2 tyrosine phosphatases to ITIMs, and ultimately opposing signals transmitted by activating receptors through dephosphorylation of proximal signaling molecules. Key inhibitory receptor on natural killer (NK) cells that regulates their activation and effector functions. 1. Sullivan, LC. et al. (2007) Immunity 27, 900-11. PMID: 18083576 2. Lin, Z. et al. (2023) Nature immunology 24, 1087-1097. PMID: 37264229 3. Valiante, NM. et al. (1997) Immunity 7, 739-51. PMID: 9430220 4. Braud, VM. et al. (1998) Nature 391, 795-9. PMID: 9486650 5. Kabat, J. et al. (2002) Journal of immunology (Baltimore, Md. : 1950) 169, 1948-58. PMID: 12165520 6. Le Dréan, E. et al. (1998) European journal of immunology 28, 264-76. PMID: 9485206 7. Kamiya, T. et al. (2019) The Journal of clinical investigation 129, 2094-2106. PMID: 30860984 8. Jabri, B. et al. (2002) Immunity 17, 487-99. PMID: 12387742 9. Bhagat, G. et al. (2008) The Journal of clinical investigation 118, 281-93. PMID: 18064301
Note	For research use only. Not suitable for clinical or therapeutic use.

Images

SDS-PAGE

SDS-PAGE for Research Grade Monalizumab.

References

Datasheet

Anti-Human NKG2A/CD159a Reference Antibody (Monalizumab, RUO).pdf

Download SDS PDF

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

Concentration

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

V₁ (Stock Vol.)

Working Solution

C₂ (Working Conc.)

V₂ (Working Vol.)

Recombinant Proteins

Antibodies

Assay Kits

Anti-Human NKG2A/CD159a Reference Antibody (Monalizumab, RUO) (HB188016)

Overview

Images

References

Datasheet

SDS

Quick access

Contact Us